RxDoctor Payments Data

Morris Roebuck, MD

Internal Medicine · Birmingham, ALNPI 1356554620

Payments from drug & device makers

$12,426in general payments, 2019–2025

Across 720 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • Bayer$908
  • Novo Nordisk$808
  • plus $5K from 37 others

What the payments were for

  • Food & beverage$12,416100%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,426 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$269,093
Medicare patients
288
Services billed
14,441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban313$213,906
JardianceEmpagliflozin157$143,162
OzempicSemaglutide96$84,904
MounjaroTirzepatide69$81,177
TrulicityDulaglutide49$63,920
SynjardyEmpagliflozin/Metformin Hcl48$37,224
XareltoRivaroxaban44$33,160
Synjardy XrEmpagliflozin/Metformin Hcl35$21,006
CreonLipase/Protease/Amylase14$20,639
Breo ElliptaFluticasone/Vilanterol39$18,902
MyrbetriqMirabegron35$18,740
GemtesaVibegron20$13,974
JanuviaSitagliptin Phosphate16$11,184
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$10,984
Aimovig AutoinjectorErenumab-Aooe12$8,566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,268$213,906313 claims
Boehringer IngelheimJardiance, Synjardy, Synjardy Xr$708$201,393240 claims
Lilly USA, LLCMounjaro, Trulicity$1,245$145,096118 claims
Novo NordiskOzempic$808$84,90496 claims
Johnson & JohnsonXarelto$563$33,16044 claims
AbbVieCreon, Namzaric, Synthroid$1,807$31,82665 claims
GSKBreo Ellipta, Trelegy Ellipta$621$29,88756 claims
Sumitomo Pharma America, Inc.Gemtesa$33$13,97420 claims
MerckJanuvia$141$11,18416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →